Clinical Trial Results:
Hyperbilirubinemia, the favourable side effect of atazanavir? Influence of atazanavir treatment on endothelial dysfunction, vascular inflammation and heme oxygenase activity in type 2 diabetes mellitus.
Summary
|
|
EudraCT number |
2008-000771-17 |
Trial protocol |
NL |
Global completion date |
01 Jan 2010
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
10 Jul 2022
|
First version publication date |
10 Jul 2022
|
Other versions |
|
Summary report(s) |
Publication 2008-000771-17 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.